Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer.

The timetable for the National Institute for Health and Care Excellence’s (NICE) guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer is still to be confirmed. Perjeta remains available to new and existing National Health Service patients through the Cancer Drugs Fund pending NICE’s final guidance.